The story has been corrected to clarify that the £36 million in total funding was awarded to several projects.
NEW YORK ─ Paige announced on Monday that the UK NHS Accelerated Access Collaborative has provided an award to the company, Oxford University, and UK National Health Service regional partners to study Paige Prostate prospectively in a cancer laboratory setting.
In total £36 million ($50.2 million) was awarded to "dozens of new pioneering projects to test state-of-the-art AI technology," according to a spokesperson. The amount awarded to Paige and its partners was not disclosed.
With the NHS award, called the Phase 4 Artificial Intelligence in Health and Care award, leaders in uropathology at Oxford University Hospitals; Coventry and Warwickshire University Hospitals Trust; and North Bristol Trust will develop adoption guidelines for the Paige Prostate diagnostic system for pathologists and other similar systems, Paige said.
The adoption guidelines will aim to enable rollout of artificial intelligence-based technologies and advanced algorithms across the NHS to help diagnose complex diseases, the company said.
The New York-based company's Paige Prostate clinical-grade, artificial intelligence-based diagnostic software system helps pathologists detect, grade, and measure prostate tumors in biopsies obtained from patients at risk of prostate cancer.
The award, restricted to market-authorized, CE-IVD-marked products, will enable Paige and its partners to evaluate the clinical or economic utility of Paige Prostate involving its use in the NHS. The partners will further aim to demonstrate the clinical and economic impact of the test in the NHS and/or social care settings to help inform reimbursement and procurement decisions and facilitate adoption, Paige said.
"Now is the time to take technologies from simulated clinical settings to embedding [them] in the routine reporting workflow and measure the impact on patient care," Clare Verrill, associate professor at Oxford University and principal study investigator for the Phase 4 award, said in a statement.
In May, Quest Diagnostics and Paige announced a collaboration to leverage Paige's machine learning expertise related to pathology diagnostic data to discover biomarkers for cancer and other diseases.